JP2023509390A - アポリポタンパク質l1特異的抗体及びその使用方法 - Google Patents

アポリポタンパク質l1特異的抗体及びその使用方法 Download PDF

Info

Publication number
JP2023509390A
JP2023509390A JP2022538362A JP2022538362A JP2023509390A JP 2023509390 A JP2023509390 A JP 2023509390A JP 2022538362 A JP2022538362 A JP 2022538362A JP 2022538362 A JP2022538362 A JP 2022538362A JP 2023509390 A JP2023509390 A JP 2023509390A
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
cdr
apol1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022538362A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023509390A5 (cg-RX-API-DMAC7.html
Inventor
スザンナ ジェーン スケーレス,
ニディ グプタ,
アンドリュー スコット ピーターソン,
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2023509390A publication Critical patent/JP2023509390A/ja
Publication of JP2023509390A5 publication Critical patent/JP2023509390A5/ja
Priority to JP2025184236A priority Critical patent/JP2026031975A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2022538362A 2019-12-23 2020-12-21 アポリポタンパク質l1特異的抗体及びその使用方法 Pending JP2023509390A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025184236A JP2026031975A (ja) 2019-12-23 2025-10-31 アポリポタンパク質l1特異的抗体及びその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962953097P 2019-12-23 2019-12-23
US62/953,097 2019-12-23
PCT/US2020/066377 WO2021133723A2 (en) 2019-12-23 2020-12-21 Apolipoprotein l1-specific antibodies and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025184236A Division JP2026031975A (ja) 2019-12-23 2025-10-31 アポリポタンパク質l1特異的抗体及びその使用方法

Publications (2)

Publication Number Publication Date
JP2023509390A true JP2023509390A (ja) 2023-03-08
JP2023509390A5 JP2023509390A5 (cg-RX-API-DMAC7.html) 2024-01-04

Family

ID=74191928

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022538362A Pending JP2023509390A (ja) 2019-12-23 2020-12-21 アポリポタンパク質l1特異的抗体及びその使用方法
JP2025184236A Pending JP2026031975A (ja) 2019-12-23 2025-10-31 アポリポタンパク質l1特異的抗体及びその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025184236A Pending JP2026031975A (ja) 2019-12-23 2025-10-31 アポリポタンパク質l1特異的抗体及びその使用方法

Country Status (16)

Country Link
US (1) US12643945B2 (cg-RX-API-DMAC7.html)
EP (1) EP4081294A2 (cg-RX-API-DMAC7.html)
JP (2) JP2023509390A (cg-RX-API-DMAC7.html)
KR (1) KR20220118527A (cg-RX-API-DMAC7.html)
CN (1) CN115515678A (cg-RX-API-DMAC7.html)
AU (1) AU2020412609A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022012439A2 (cg-RX-API-DMAC7.html)
CA (1) CA3165504A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022001714A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022010235A2 (cg-RX-API-DMAC7.html)
CR (1) CR20220334A (cg-RX-API-DMAC7.html)
IL (1) IL294131A (cg-RX-API-DMAC7.html)
MX (1) MX2022007746A (cg-RX-API-DMAC7.html)
PE (1) PE20221186A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022551496A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021133723A2 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024203942A1 (ja) * 2023-03-24 2024-10-03 デンカ株式会社 バキュロウイルス発現ベクターシステムにおける遺伝子組換えタンパク質の製造方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240004937A (ko) 2021-05-05 2024-01-11 이매틱스 바이오테크놀로지스 게엠베하 Bma031 항원 결합 폴리펩타이드
WO2023086901A1 (en) * 2021-11-12 2023-05-19 Virginia Tech Intellectual Properties, Inc. Borrelia burgdorferi peptidoglycan detection methods
MX2024008868A (es) 2022-01-18 2024-09-23 Maze Therapeutics Inc Inhibidores de la apolipoproteína l1 (apol1) y métodos de uso.
KR20240154675A (ko) * 2022-03-16 2024-10-25 주식회사 에스티큐브앤컴퍼니 Btn1a1 결합 단백질 및 이의 이용 방법
WO2024050524A1 (en) * 2022-09-01 2024-03-07 University Of Georgia Research Foundation, Inc. Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death
EP4709421A2 (en) * 2023-05-09 2026-03-18 Virginia Tech Intellectual Properties, Inc. B. burgdorferi peptidoglycan antibodies and uses thereof
WO2024242903A1 (en) * 2023-05-22 2024-11-28 Albert Einstein College Of Medicine Antibodies targeting s100 proteins and uses thereof
CN121794301A (zh) * 2023-09-23 2026-04-03 安捷伦科技有限公司 用于体外诊断学的抗人adam9抗体

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018500882A (ja) * 2014-11-10 2018-01-18 ジェネンテック, インコーポレイテッド 腎症の動物モデルおよびそれを治療するための薬剤

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
EP0979281B1 (en) 1997-05-02 2005-07-20 Genentech, Inc. A method for making multispecific antibodies having heteromultimeric and common components
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US6004925A (en) 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
CA2378403A1 (en) 1999-07-26 2001-02-01 Genentech, Inc. Novel polynucleotides and method for the use thereof
KR100797667B1 (ko) 1999-10-04 2008-01-23 메디카고 인코포레이티드 외래 유전자의 전사를 조절하는 방법
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
PT2857516T (pt) 2000-04-11 2017-08-28 Genentech Inc Anticorpos multivalentes e utilizações dos mesmos
EP1534320B1 (en) 2002-08-02 2006-11-22 Universite Libre De Bruxelles Apolipoprotein l-i for the treatment of trypanosomal diseases
AU2004242846A1 (en) 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
US8236308B2 (en) 2005-10-11 2012-08-07 Micromet Ag Composition comprising cross-species-specific antibodies and uses thereof
US20080044455A1 (en) 2006-08-21 2008-02-21 Chaim Welczer Tonsillitus Treatment
EP2471816A1 (en) 2006-08-30 2012-07-04 Genentech, Inc. Multispecific antibodies
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
WO2008119567A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific cd3-epsilon binding domain
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
BRPI1014089A2 (pt) 2009-04-02 2016-04-19 Roche Glycart Ag anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simples
PT2417156E (pt) 2009-04-07 2015-04-29 Roche Glycart Ag Anticorpos trivalentes, biespecíficos
SG176219A1 (en) 2009-05-27 2011-12-29 Hoffmann La Roche Tri- or tetraspecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
CN102712696A (zh) 2009-09-16 2012-10-03 弗·哈夫曼-拉罗切有限公司 包含卷曲螺旋和/或系链的蛋白质复合体及其用途
KR101870555B1 (ko) 2011-08-23 2018-06-22 로슈 글리카트 아게 T 세포 활성화 항원 및 종양 항원에 대해 특이적인 이중특이적 항체 및 이의 사용 방법
LT2748201T (lt) 2011-08-23 2018-02-26 Roche Glycart Ag Dvigubai specifinė t ląsteles aktyvinantį antigeną surišanti molekulė
KR101721301B1 (ko) 2011-08-23 2017-03-29 로슈 글리카트 아게 이중특이적 항원 결합 분자
CN104781275A (zh) 2012-11-16 2015-07-15 默沙东公司 修饰的apol1多肽
BR112016011027A2 (pt) 2013-12-20 2017-12-05 Genentech Inc método de produção de um anticorpo, anticorpos, composição farmacêutica, polinucleotídeo, vetor, célula hospedeira, método de tratamento de asma e método de tratamento de um distúrbio
UA117289C2 (uk) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
EP3174897B1 (en) 2014-07-29 2020-02-12 F.Hoffmann-La Roche Ag Multispecific antibodies
PL3177643T3 (pl) 2014-08-04 2019-09-30 F.Hoffmann-La Roche Ag Dwuswoiste cząsteczki wiążące antygen aktywujące komórki T
CA2980189A1 (en) 2015-04-24 2016-10-27 Genentech, Inc. Multispecific antigen-binding proteins
CN107782904A (zh) 2016-08-26 2018-03-09 武汉三鹰生物技术有限公司 一种用于载脂蛋白l1的酶联免疫检测及制备方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018500882A (ja) * 2014-11-10 2018-01-18 ジェネンテック, インコーポレイテッド 腎症の動物モデルおよびそれを治療するための薬剤

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ALLISON WECKERLE; ET AL: "CHARACTERIZATION OF CIRCULATING APOL1 PROTEIN COMPLEXES IN AFRICAN AMERICANS", JOURNAL OF LIPID RESEARCH, vol. VOL:57, NR:1, JPN5023004076, 2016, US, pages 120 - 130, ISSN: 0005475027 *
GUPTA NIDHI; ET AL: "DOMAIN-SPECIFIC ANTIBODIES REVEAL DIFFERENCES IN THE MEMBRANE TOPOLOGIES OF APOLIPOPROTEIN L1 IN SER", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, vol. VOL:31, NR:9, JPN5023004078, September 2020 (2020-09-01), US, pages 2065 - 2082, ISSN: 0005475029 *
JUSTIN CHUN; ET AL: "RECRUITMENT OF APOL1 KIDNEY DISEASE RISK VARIANTS TO LIPID DROPLETS ATTENUATES CELL TOXICITY", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES(PNAS), vol. VOL:116, NR:9, JPN5023004077, 7 February 2019 (2019-02-07), US, pages 3712 - 3721, ISSN: 0005475028 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024203942A1 (ja) * 2023-03-24 2024-10-03 デンカ株式会社 バキュロウイルス発現ベクターシステムにおける遺伝子組換えタンパク質の製造方法

Also Published As

Publication number Publication date
PH12022551496A1 (en) 2023-12-11
WO2021133723A3 (en) 2021-08-05
AU2020412609A1 (en) 2022-06-16
PE20221186A1 (es) 2022-08-05
MX2022007746A (es) 2022-10-07
KR20220118527A (ko) 2022-08-25
WO2021133723A2 (en) 2021-07-01
JP2026031975A (ja) 2026-02-25
BR112022012439A2 (pt) 2022-09-06
EP4081294A2 (en) 2022-11-02
US12643945B2 (en) 2026-06-02
CN115515678A (zh) 2022-12-23
CL2022001714A1 (es) 2023-03-03
CA3165504A1 (en) 2021-07-01
CO2022010235A2 (es) 2022-08-09
IL294131A (en) 2022-08-01
US20230071609A1 (en) 2023-03-09
CR20220334A (es) 2022-08-26

Similar Documents

Publication Publication Date Title
US20230071609A1 (en) Apolipoprotein L1-Specific Antibodies and Methods of Use
US20240052021A1 (en) Anti-c5 antibodies and methods of use
US20240067752A1 (en) ANTI-HtrA1 ANTIBODIES AND METHODS OF USE THEREOF
RU2742606C2 (ru) Антитела к с5 и способы их применения
CN111556895B (zh) 抗-c1s抗体及使用方法
CA3012720C (en) Frizzled5 protein-binding agents
TWI856193B (zh) 抗體、醫藥組成物及方法
AU2017285763A1 (en) Anti-C5 antibodies and methods of use
KR102967554B1 (ko) 항C1s 항체
MX2014008157A (es) Anticuerpos anti-lrp5 y metodos de uso.
JP2025031859A (ja) 抗原結合分子、薬学的組成物、および方法
JP2024512377A (ja) 抗klk7抗体、抗klk5抗体、多重特異性抗klk5/klk7抗体、及び使用方法
KR20220092859A (ko) 항-cxcr2 항체 및 이의 용도
HK40085952A (en) Apolipoprotein l1-specific antibodies and methods of use
JP7753313B2 (ja) 抗C1s抗体の使用
JP2018500882A (ja) 腎症の動物モデルおよびそれを治療するための薬剤
RU2789788C2 (ru) Антитела к с5 и способы их применения
CN121909210A (zh) 与C3bBb结合的抗体
HK40120050A (en) An antigen-binding molecule, a pharmaceutical composition, and a method
KR20240054896A (ko) 항C1s 항체의 사용
HK40010475B (en) Gremlin-1 crystal structure and inhibitory antibody
EA041632B1 (ru) Антитела к с5 и способы их применения
HK1180347A (en) Anti-neuropilin antibodies and methods of use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231221

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250226

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250424

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250603

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250701